Schroder UK Public Private Trust (GB:INOV) has released an update.
Schroders Capital Global Innovation Trust plc has announced a second follow-on investment of £1.4 million into iOnctura BV, a biotech firm developing treatments for challenging cancers, including a promising drug for uveal melanoma. The investment contributes to a £68 million funding round aimed at accelerating the development of iOnctura’s innovative cancer therapies. With a focus on life science companies in near-clinical or clinical stages, the Trust’s total investment in iOnctura has reached £2.8 million.
For further insights into GB:INOV stock, check out TipRanks’ Stock Analysis page.
